CRSP241213C53000
- 0.05
- +0.02+66.67%
CRISPR Therapeutics Newsroom
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $94
Evercore Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
Crispr Therapeutics AG (CRSP) Gets a Hold From Evercore ISI
Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)
Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $94 Price Target
CRISPR Therapeutics Analyst Ratings
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Vertex Reports Positive Long-term Data for Casgevy
CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock?
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
What CRISPR Therapeutics AG's (NASDAQ:CRSP) P/S Is Not Telling You
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating